Literature DB >> 10497156

p48 (ISGF-3gamma) is involved in interferon-alpha-induced suppression of hepatitis B virus enhancer-1 activity.

K Nakao1, K Nakata, M Yamashita, Y Tamada, K Hamasaki, H Ishikawa, Y Kato, K Eguchi, N Ishii.   

Abstract

Interferon-alpha (IFN-alpha) suppresses hepatitis B virus (HBV) gene expression by reducing its enhancer-1 activity. IFN-alpha induces transcription factors, interferon-stimulated gene factor 3 (ISGF3), and interferon regulatory factor-1 (IRF-1), which activate interferon-inducible gene expression through binding to the interferon-stimulated regulatory element (ISRE) "AGTTTCNNTTTCNC" in the gene promoters. We found the ISRE-like sequence "AGGCTTTCACTTTCTC" in the HBV enhancer-1 region and elucidated the role of this sequence. Gel mobility shift assay showed binding of in vitro translated IRF-1 and in vitro translated p48 (ISGF3-gamma), which is a component of ISGF3 to this sequence. However, nuclear extracts binding to this sequence from human hepatoma cells (HuH-7) treated with IFN-alpha contained only the protein consisted of p48. In transfection experiments, IFN-alpha suppressed the HBV enhancer-1 activity, and overexpression of p48 enhanced this inhibitory effect. Both mutation and deletion of the ISRE-like sequence in the HBV enhancer-1 region reduced the suppressive effect of IFN-alpha. Our results suggest that the ISRE-like sequence in the HBV enhancer-1 can interact with the protein containing p48 and mediate the IFN-alpha-induced suppression of the enhancer activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497156     DOI: 10.1074/jbc.274.40.28075

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence.

Authors:  Isha Sengupta; Dipanwita Das; Shivaram Prasad Singh; Runu Chakravarty; Chandrima Das
Journal:  J Biol Chem       Date:  2017-10-18       Impact factor: 5.157

2.  Adenovirus sequesters phosphorylated STAT1 at viral replication centers and inhibits STAT dephosphorylation.

Authors:  Sook-Young Sohn; Patrick Hearing
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

Review 3.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome.

Authors:  Flavio F Alcantara; Hong Tang; Alan McLachlan
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

5.  Functional Characterization of Interferon Regulation Element of Hepatitis B virus Genome In Vivo.

Authors:  Feng-Jun Liu; En-Qiang Chen; Qiao-Ling Zhou; Tao-You Zhou; Cong Liu; Li Liu; Xing Cheng; Hong Tang
Journal:  Indian J Virol       Date:  2012-09-06

Review 6.  Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways.

Authors:  Rong-Juan Pei; Xin-Wen Chen; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients.

Authors:  Jia-Jie Lu; En-Qiang Chen; Jia-Hong Yang; Tao-You Zhou; Li Liu; Hong Tang
Journal:  Virol J       Date:  2012-01-10       Impact factor: 4.099

8.  Negative feedback circuit for toll like receptor-8 activation in human embryonic Kidney 293 using outer membrane vesicle delivered bi-specific siRNA.

Authors:  Anurag Adhikari; Birendra Prasad Gupta; Krishna Das Manandhar; Shravan Kumar Mishra; Hari Krishna Saiju; Rajendra Maan Shrestha; Nawneet Mishra; Shishir Sharma
Journal:  BMC Immunol       Date:  2015-07-23       Impact factor: 3.615

Review 9.  Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.

Authors:  Zhi Yi Goh; Ee Chee Ren; Hui Ling Ko
Journal:  World J Gastroenterol       Date:  2021-04-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.